Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report)'s share price shot up 6.6% during trading on Thursday . The stock traded as high as $20.00 and last traded at $19.90. 1,545,411 shares changed hands during mid-day trading, an increase of 71% from the average session volume of 906,016 shares. The stock had previously closed at $18.66.
Wall Street Analyst Weigh In
Several equities research analysts have weighed in on CLDX shares. The Goldman Sachs Group lowered their target price on Celldex Therapeutics from $36.00 to $31.00 and set a "neutral" rating for the company in a report on Friday, May 9th. UBS Group decreased their target price on Celldex Therapeutics from $44.00 to $38.00 and set a "buy" rating on the stock in a research report on Friday, May 9th. HC Wainwright restated a "buy" rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a report on Tuesday, May 6th. Canaccord Genuity Group started coverage on Celldex Therapeutics in a research report on Monday, April 28th. They set a "buy" rating and a $64.00 price objective for the company. Finally, Morgan Stanley cut their price target on Celldex Therapeutics from $46.00 to $43.00 and set an "overweight" rating for the company in a research note on Friday, May 9th. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Celldex Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $53.90.
Get Our Latest Stock Analysis on Celldex Therapeutics
Celldex Therapeutics Stock Performance
The stock has a market capitalization of $1.29 billion, a P/E ratio of -7.58 and a beta of 1.39. The stock has a 50-day simple moving average of $18.87 and a 200 day simple moving average of $22.14.
Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last posted its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.06). Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. The firm had revenue of $0.70 million during the quarter, compared to analyst estimates of $1.08 million. Equities analysts predict that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current year.
Hedge Funds Weigh In On Celldex Therapeutics
Several hedge funds have recently modified their holdings of the company. Rhumbline Advisers boosted its stake in shares of Celldex Therapeutics by 6.9% during the first quarter. Rhumbline Advisers now owns 98,266 shares of the biopharmaceutical company's stock valued at $1,784,000 after purchasing an additional 6,327 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Celldex Therapeutics by 12.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 131,296 shares of the biopharmaceutical company's stock valued at $2,383,000 after purchasing an additional 14,979 shares during the last quarter. Millennium Management LLC lifted its holdings in shares of Celldex Therapeutics by 327.3% in the 1st quarter. Millennium Management LLC now owns 399,932 shares of the biopharmaceutical company's stock worth $7,259,000 after buying an additional 306,330 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Celldex Therapeutics by 1.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,451 shares of the biopharmaceutical company's stock valued at $798,000 after buying an additional 680 shares in the last quarter. Finally, ADAR1 Capital Management LLC acquired a new position in shares of Celldex Therapeutics in the first quarter valued at about $265,000.
Celldex Therapeutics Company Profile
(
Get Free Report)
Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.
Featured Stories
Before you consider Celldex Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celldex Therapeutics wasn't on the list.
While Celldex Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
